NEW YORK, Jan. 22, 2024 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (ImmunoBrain), a clinical stage biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced the appointment of Dr. Sanjay Keswani, MD, BSc, FRCP, as its President and Chief Executive Officer.
ImmunoBrain Checkpoint (IBC) has announced the dosing of the first two patients in a Phase Ib trial of IBC-Ab002 to treat patients with early Alzheimer’s disease.
NEW YORK, May 17, 2023 /PRNewswire/ -- ImmunoBrain Checkpoint Inc. (IBC), a biopharmaceutical company developing innovative disease-modifying immune therapies to combat neurodegenerative diseases, today announced that it has dosed the first two patients in the Phase 1b IBC-01-01 clinical trial investigating IBC's lead program, IBC-Ab002 for patients with early Alzheimer's disease. IBC-Ab002 is a novel, fully human anti-PD-L1 monoclonal antibody designed to harness the peripheral immune system to help the brain overcome the multiple pathological factors that contribute to the cognitive manifestation and progression of neurodegenerative diseases, including local brain inflammation, amyloid beta, tau pathologies and neuronal loss.
NEW YORK, Friday August 27, 2021 – ImmunoBrain Checkpoint Inc. (“IBC”) an innovative biopharmaceutical company developing potential disease-modifying immune therapies that harness the power of the immune system to help protect and repair the brain to combat neurodegenerative diseases, announced today that the National Institute on Aging (NIA) of the US National Institutes of Health (NIH) has awarded the Company a grant totaling $5 million over three years to support a first-in-human clinical study of IBC-Ab002, for the treatment of Alzheimer’s disease.